• Something wrong with this record ?

Lack of correlation of stem cell markers in breast cancer stem cells

Y. Liu, R. Nenutil, MV. Appleyard, K. Murray, M. Boylan, AM. Thompson, PJ. Coates,

. 2014 ; 110 (8) : 2063-71.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

E-resources Online Full text

NLK Free Medical Journals from 1947 to 1 year ago
Freely Accessible Journals from 1947 to 1 year ago
PubMed Central from 1947 to 1 year ago
Europe PubMed Central from 1947 to 1 year ago
ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1947-01-01
Open Access Digital Library from 1999-01-01
Medline Complete (EBSCOhost) from 1999-01-01 to 2015-11-17
Nursing & Allied Health Database (ProQuest) from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago
Public Health Database (ProQuest) from 2000-01-01 to 1 year ago

BACKGROUND: Various markers are used to identify the unique sub-population of breast cancer cells with stem cell properties. Whether these markers are expressed in all breast cancers, identify the same population of cells, or equate to therapeutic response is controversial. METHODS: We investigated the expression of multiple cancer stem cell markers in human breast cancer samples and cell lines in vitro and in vivo, comparing across and within samples and relating expression with growth and therapeutic response to doxorubicin, docetaxol and radiotherapy. RESULTS: CD24, CD44, ALDH and SOX2 expression, the ability to form mammospheres and side-population cells are variably present in human cancers and cell lines. Each marker identifies a unique rather than common population of cancer cells. In vivo, cells expressing these markers are not specifically localized to the presumptive stem cell niche at the tumour/stroma interface. Repeated therapy does not consistently enrich cells expressing these markers, although ER-negative cells accumulate. CONCLUSIONS: Commonly employed methods identify different cancer cell sub-populations with no consistent therapeutic implications, rather than a single population of cells. The relationships of breast cancer stem cells to clinical parameters will require identification of specific markers or panels for the individual cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14063703
003      
CZ-PrNML
005      
20140707132035.0
007      
ta
008      
140704s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/bjc.2014.105 $2 doi
035    __
$a (PubMed)24577057
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Liu, Y $u 1] Dundee Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK [2].
245    10
$a Lack of correlation of stem cell markers in breast cancer stem cells / $c Y. Liu, R. Nenutil, MV. Appleyard, K. Murray, M. Boylan, AM. Thompson, PJ. Coates,
520    9_
$a BACKGROUND: Various markers are used to identify the unique sub-population of breast cancer cells with stem cell properties. Whether these markers are expressed in all breast cancers, identify the same population of cells, or equate to therapeutic response is controversial. METHODS: We investigated the expression of multiple cancer stem cell markers in human breast cancer samples and cell lines in vitro and in vivo, comparing across and within samples and relating expression with growth and therapeutic response to doxorubicin, docetaxol and radiotherapy. RESULTS: CD24, CD44, ALDH and SOX2 expression, the ability to form mammospheres and side-population cells are variably present in human cancers and cell lines. Each marker identifies a unique rather than common population of cancer cells. In vivo, cells expressing these markers are not specifically localized to the presumptive stem cell niche at the tumour/stroma interface. Repeated therapy does not consistently enrich cells expressing these markers, although ER-negative cells accumulate. CONCLUSIONS: Commonly employed methods identify different cancer cell sub-populations with no consistent therapeutic implications, rather than a single population of cells. The relationships of breast cancer stem cells to clinical parameters will require identification of specific markers or panels for the individual cancer.
650    _2
$a antigen CD24 $x biosyntéza $x imunologie $7 D051927
650    _2
$a antigeny CD44 $x biosyntéza $x imunologie $7 D018960
650    _2
$a nádory prsu $x genetika $x metabolismus $x patologie $7 D001943
650    _2
$a chemorezistence $x genetika $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a MFC-7 buňky $7 D061986
650    _2
$a nádorové kmenové buňky $x metabolismus $7 D014411
650    _2
$a transkripční faktory SOXB1 $x biosyntéza $x imunologie $7 D055748
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nenutil, R $u Regional Centre for Applied Molecular Oncology, Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
700    1_
$a Appleyard, M V $u Dundee Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. $7 gn_A_00007858
700    1_
$a Murray, K $u Dundee Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.
700    1_
$a Boylan, M $u Dundee Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.
700    1_
$a Thompson, A M $u 1] Dundee Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK [2] Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.
700    1_
$a Coates, P J $u Dundee Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.
773    0_
$w MED00009369 $t British journal of cancer $x 1532-1827 $g Roč. 110, č. 8 (2014), s. 2063-71
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24577057 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140707132324 $b ABA008
999    __
$a ok $b bmc $g 1031187 $s 862435
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 110 $c 8 $d 2063-71 $i 1532-1827 $m British journal of cancer $n Br J Cancer $x MED00009369
LZP    __
$a Pubmed-20140704

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...